Myeloma Paper of the Day, September 5th, suggested by Robert Orlowski

Robert Orlowski shared on X:

“Myeloma Paper of the Day: Metformin augments GPRC5D expression in multiple myeloma and enhances the efficacy of GPRC5D-CAR T cells in pre-clinical in vitro models.”

Source: Robert Orlowski/X

Metformin augments GPRC5D in multiple myeloma and enhances the efficacy of GPRC5D-CAR T cells

Authors: Xiaoli Hu, Xinyi Zhou, Qian Zhao, Ying Yang, Yang Liang, Yuchen Xiao, Zhuoqun Liu, Liu Liu, Chao Zhang and Juan Du.

Other posts featuring Robert Orlowski on OncoDaily.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.